Matthew J. Chung

1 YEAR AGO TODAY! Every interventional cardiologist will always remember their first independent #STEMI. Mine came right away on my first night on call!  6 Fr RRA, #IVUS-guided to confirm intraluminal position (very difficult to wire ISR, acted like an acute on chronic CTO). . .

This RCT provides evidence that 6-month smartwatch-based #AFib screening enhances the detection rate of new onset AF compared with standard care in patients at elevated stroke risk. jacc.org/doi/10.1016/j.… #JACC #DigitalHealth #ECG

Among 562 older adults undergoing #TAVR, the novel GASS-TAVR score — incorporating nutrition, BADL, renal function & pulmonary pressure — predicted 1-yr mortality or functional decline w/ AUC 0.92, outperforming STS score in this #JACCINT multicenter study jacc.org/doi/10.1016/j.…

JUST OUT #JAMA the real-world US experience of Evoque #TTVR in >1000 pts from the TVT registry, showing encouraging 30d outcomes vs TRISCEND 2, among 82 trial and early commercial sites, with early commercial experience. Key takeaways: - Mean age 77, 69% female, 73% NYHA III/IV, 91% prior HFH, 84% AF, 38% prior CIED, 68% on anticoagulation - 40/40 split on primary vs secondary TR, 9% CIED related TR - Interestingly, 40% mod/severe MR! - 26 cases done via IJ - 50/50 split between 44/48 vs 52/56 mm sizes - 1 TTVR embolization/6 migration (in-hospital, none after), 8 acute surgical conversion, LOS 2 days post TTVR, 94% D/C home - 30d: 3% all-cause, 2% CV mortality, 3.1% HFH, 15.9% pacemaker, 1.4% bleeding at access site / major vascular complication, 2.2% unplanned cardiac interventions, 1.3% cardiac arrest, 0.5% TV reintervention, 0.4% lead dislodgement/dysfunction, 0.6% cardiac perforation - 98% mild or less TR, near TR elmination - 94% on anticoagulation post TTVR - Predictor of pacemaker: larger Evoque sizes; no predictors of bleeding Pretty remarkable results in this sick population requiring complex TEE +/- ICE guidance. We are proud to be one of the early commercial sites to offer this therapy to our patients @MountSinaiHeart Congrats to all investigators for their brave efforts in bringing this therapy to US patients! Future procedural and technology refinements should improve this therapy further! FULL TEXT here: jamanetwork.com/journals/jama/… @MountSinaiNYC @IcahnMountSinai @DoctorKini @KHERA_MD @LucySafi @georgedangas @DLBHATTMD @Dr_BrendanCarr @DrDavidReich @BethOliverVP

Early U.S. experience with the Navitor valve demonstrates favorable early clinical and hemodynamic outcomes, with improved #PPI rate associated with procedural experience. jacc.org/doi/10.1016/j.… #JACCINT #TAVR #TVTRegistry @GilbertTangMD @KHERA_MD @PradeepYadavMD

Thank you to everyone who joined us at #ARCH2026! Save the Date - ARCH will be back again at The Ritz-Carlton on April 14-17, 2027! #Cardiology #InterventionalCardiology #CardioTwitter #CardioX #Cardiologist #Nurse #CME

Orthotopic #TTVR with transvalvular #CIED leads is safe with low lead failure. Jailed leads have higher PVL and residual TR. Close CIED follow-up and backup pacing are key, especially if pacing-dependent. jacc.org/doi/10.1016/j.… #JACCCEP #EPeeps

A new #ACC26 study found that people who consumed over 9 servings of ultra-processed 🍪🍟🍕 foods per day faced a 47% higher risk of #CVD, including heart attack & #stroke. Find out more with @foodandwine: bit.ly/4lOVKSo @amierhaidar

Finally published: the COBRRA trial, the first randomized head-to-head comparison of major DOACs — something the companies would never have done themselves, as a direct confrontation goes beyond their commercial interests. This was driven by independent investigators. The results somewhat support the idea of apixaban being the “safer” DOAC. That said, the list of study limitations is long, and for me, labeling something as “safe” is not enough — after all, even placebo is “safe” when it comes to bleeding. nejm.org/doi/full/10.10…

Fibrotic THV frame ingrowth is a common phenomenon that may complicate THV explantation and impede neosinus washout and coronary access after #TAVR. jacc.org/doi/10.1016/j.… #JACCINT

Latest #JACCINT randomized trial 📊 compares balloon lithotripsy 💥vs conventional prep in severely calcified coronaries. Lithotripsy cut procedural or target vessel failure at 1 year 📉, mainly by reducing residual stenosis 🔍✨ jacc.org/doi/10.1016/j.…

Ex-vivo study of 23 to 34 mm Evolut THVs: IFU-guided post-dilation preserved frame geometry and leaflet integrity. Oversized balloons caused waist over-expansion and immediate leaflet tears. jacc.org/doi/10.1016/j.… #JACCINT

In #JACC, diet quality was more strongly assoc w/ #CHD risk than macronutrient quantity. High-quality low-carb & low-fat patterns were linked to lower risk, while versions high in refined carbs & animal products were assoc w/ higher CHD risk jacc.org/doi/10.1016/j.… #HFWeek2026

New Balloon-Expandable Valve! #DURAVR bit.ly/DURAVR_SmallAnn Changing the discussion of Small annulus AS? @EuroInterventio #EuroPCR @EAPCIPresident @escardio @ACCinTouch

In this study of #TTVR patients, HALT and RLM CT were common & associated with ⬆️gradients & ⬇️symptomatic alleviation. Transthoracic echocardiography is insensitive for detecting HALT & RLM. CT may aid early diagnosis jacc.org/doi/10.1016/j.… #JACCINT #cvEcho

JUST OUT! #JACCINT @JACCJournals on long-term outcomes of SAPIEN3 MVIV MVIR VIMAC #TMVR. As expected, MVIV did much better than MVIR and VIMAC in all-cause and CV mortality. Median follow-up 3ys (up to 8y) with ~7% severe SVD after 5y and ~10% TMVR failure after 4y. Depends on how you see it, I see this as sobering outcomes: MVIR and VIMAC should be offered only in inoperable patients with limited life expectancies, given poor survival and limited valve durability. MVIV has better outcomes, but need to follow re: SVD and TMVR failure and may end up being a bridge to reop MVR especially in younger patients. 5y durability data of native TMVR are emerging (Intrepid, Tendyne), will see how they fare vs balloon-expandable TMVR in failed valves, rings, MAC. Thoughts and comments? jacc.org/doi/full/10.10…

This retrospective study found that #TTVR is associated with ⬇️ in LV eccentricity with ⬆️in forward SV. CT measures of RV function (effective RVEF) & RV coupling (SV/ESV) both improve following TTVR. jacc.org/doi/10.1016/j.… #JACCINT #CardioX @hahn_rt @laurenranard

Conservative management of #FFR ≤0.80 lesions was linked to higher cardiovascular risk compared with either #PCI of FFR ≤0.80 lesions or deferral of FFR >0.80 lesions, which had similar outcomes. jacc.org/doi/10.1016/j.… #JACCINT #TAVR

Stubborn #TIMI5CoronaryThrombus not responding to #MechanicalThrombectomy? Try the new #CatPounceTechnique published in @InvasiveCardiol hmpgloballearningnetwork.com/site/jic/clini… @KardiologieHH @mirvatalasnag @stefan_harb @VladLakhter @SripalBangalore @DrJayMohan @jaygirimd @timir_paul @BakhshiHooman @agtruesdell @ziadalinyc @adityadoc1 @MichaelMegalyMD @FadiSaab17 @AntoniousAttall @realarainmd @mobitz @DeepBlueDoc21 @kevinjamescroce @EricSecemskyMD @gbiondizoccai @aayshacader @Pooh_Velagapudi @baileyannRN @DFCapodanno @piccoloraf @MarwanSaadMD @sanjum @sahilparikhmd @EAPCIPresident @CardioNerds @Cardio_Vumedi @TCTMD @KateKearney4 @MatthiesenTimm @adnanalkhouli @AnkurKalraMD @andresvargasECU @evandrofilhobr @SukhNijjer @DrDamluji @lindsey_cilia @AGoldsweig @SVRaoMD @ekgpdx @Babar_Basir @herbaronowMD @ChetRihal

The authors present the largest series of #TTVR after T-TEER with electrosurgical leaflet modification in a subset of patients. At 30 days, TR severity was markedly reduced, and substantial symptom alleviation occurred. jacc.org/doi/10.1016/j.… #JACCINT #vhdTR #TEER @jtsaxon

Great MMI session on AS Evaluation #EACVI2025 See highlights below. @escardio @EACVIPresident